Medical retinal imaging company Optos plc has delivered its first next-generation ultra-widefield retinal imaging devices (Daytona) to customers. The new devices have been scaled to accommodate smaller office spaces while providing high-resolution imaging and adding new autofluorescence capabilities.
London-Medical retinal imaging company Optos plc has delivered its first next-generation ultra-widefield retinal imaging devices (Daytona) to customers. The new devices have been scaled to accommodate smaller office spaces while providing high-resolution imaging and adding new autofluorescence capabilities.
According to Optos, the devices feature a new, ergonomic body designed to increase patient comfort as well as make it easier to position the eye correctly; an improved user interface with an intuitive, workflow-based software; “plug-and-play” installation; image review capabilities; and electronic image storage options. The device was designed to allow the globalization of the company’s core imaging technology.
“We are pleased to announce shipment of our first devices on schedule,” said Roy Davis, chief executive officer, Optos plc. “Following the unveiling of [the next-generation devices] in October, we have seen growing demand for the product, and over the coming months we will be increasing our manufacturing capacity accordingly. We believe [these devices] represent an excellent growth opportunity for Optos.”
For more articles in this issue of Ophthalmology Times eReport, click here.
